Producer licensing and carrier appointments sit at the center of every insurance agency acquisition. This article maps the regulatory framework governing license survival, appointment transferability, DRLP continuity, and state DOI notification obligations from letter of intent through post-close integration.
Insurance producer licensing in the United States is entirely state-driven. There is no federal producer license. Each of the fifty states, the District of Columbia, and the U.S. territories administers its own licensing regime, sets its own qualification requirements, and retains independent authority to discipline or revoke licenses. The result for M&A counsel is that a multi-state insurance agency may hold dozens of distinct licenses, each governed by a different regulatory authority.
The National Association of Insurance Commissioners has worked for decades to reduce fragmentation through the Uniform Licensing Standards initiative, also known as the Producer Licensing Model Act. The PLMA establishes a common framework covering license classes, examination requirements, continuing education, and reciprocal licensing for nonresident producers. As of the current period, most states have adopted the PLMA in substantially similar form, which meaningfully reduces the variance in core licensing rules.
The NAIC ULS program goes further, evaluating states on their actual implementation of uniform standards. States that achieve full compliance with ULS benchmarks participate in reciprocal licensing arrangements that allow producers licensed in their home state to obtain nonresident licenses in reciprocal states without sitting for additional examinations. This reciprocity infrastructure is critical for agencies with national books of business, because it determines whether a post-acquisition licensing campaign can be executed efficiently or requires state-by-state examination and qualification.
Understanding the PLMA framework and ULS compliance map is the first step in any insurance agency M&A licensing diligence. Counsel must identify the target's home state, map which states are reciprocal, and assess whether any states in the target's footprint impose idiosyncratic requirements outside the uniform framework. States that have not achieved ULS compliance or that have adopted the PLMA with material variations require individualized analysis. The regulatory map shapes the entire licensing transition timeline and directly affects the feasibility of closing on the contemplated schedule.
The NAIC also maintains the State Based Systems, or SBS, database, which is the repository of entity and individual producer licensing data for participating states. SBS integrates with NIPR (covered in Section 3) to provide a near-real-time view of license status across jurisdictions. Diligence teams should pull SBS records for all states in the target's footprint as an early step in licensing diligence to confirm the current license inventory before relying on representations in the purchase agreement.
Insurance agencies operate under two parallel licensing regimes: entity licenses and individual producer licenses. Distinguishing between them is foundational to M&A licensing analysis, because they are issued to different parties, governed by different rules, and respond differently to a change-of-control event.
An entity license, sometimes called a business entity license or agency license, is issued to the corporate entity itself, whether a corporation, LLC, partnership, or other legal form. It authorizes that entity to transact insurance as an organization. The entity license is what allows the agency to operate as a business, collect premiums, bind coverage, and hold itself out to the public as a licensed insurance agency. Entity licenses typically require designation of a DRLP (discussed in Section 8), maintenance of a registered office, and compliance with ongoing reporting obligations to the state DOI.
Individual producer licenses are issued to natural persons. They authorize those individuals to sell, solicit, or negotiate insurance in the licensed lines of authority in the issuing state. An individual who produces business through the agency must hold their own individual license in each state where they transact business. The individual's license is not derived from or dependent on the entity license. Both must be in good standing for the agency to operate lawfully.
In M&A due diligence, both license types must be inventoried independently. The entity license inventory establishes where the agency is authorized to operate as a business. The individual license inventory identifies which producers hold authority in which states and lines, and flags any gaps between where producers are transacting business and where they hold licenses. Gaps in individual licensing are a material compliance risk that must be disclosed and remediated, because unlicensed activity by an individual is a regulatory violation regardless of whether the entity holds a license for that state.
The structure of the transaction, stock versus asset, affects the two license types differently. In a stock sale, the entity license continues in the same legal entity and generally survives. Individual licenses are unaffected by the ownership change at the entity level. In an asset sale, neither the entity license nor individual licenses transfer automatically. The acquiring entity must apply for new entity licenses, and individual producers must obtain licenses in the acquiring entity's name if they are moving to a new legal entity. This distinction is one of the most consequential structural considerations in insurance agency M&A.
The National Insurance Producer Registry is the centralized electronic gateway through which producers, agencies, and regulators interact on licensing transactions. NIPR is a nonprofit affiliate of the NAIC and serves as the primary submission channel for license applications, amendments, renewals, and certain change-of-information filings across participating states. For M&A practitioners, NIPR is the operational infrastructure through which multi-state licensing transitions are executed.
NIPR's Producer Database, or PDB, is the authoritative repository of individual producer licensing data for nearly all states. It aggregates license records, appointment data, and regulatory action history from state DOI systems into a single searchable interface. In diligence, the PDB provides a rapid multi-state license search for individual producers, surfacing license status, expiration dates, lines of authority, and any adverse regulatory history. Running PDB searches on all key producers and the entity itself is standard practice in insurance agency diligence.
NIPR's gateway service enables electronic submission of license applications and amendments to participating states. Most nonresident license applications can be filed through NIPR's online portal, with the application routed electronically to each recipient state's DOI. States that have integrated their licensing systems with NIPR's gateway can process and approve applications with minimal manual intervention, substantially accelerating the licensing timeline for multi-state campaigns. States that are not fully integrated require separate paper or portal applications, adding time and administrative complexity.
NIPR also facilitates appointment transactions, allowing carriers to submit appointment and termination filings electronically to participating states. This is significant in M&A contexts where the acquirer is managing carrier appointment re-filings across multiple carriers and multiple states simultaneously. Understanding NIPR's appointment filing capabilities and the integration status of each state in the target's footprint allows counsel and the licensing team to develop a realistic operational plan for the appointment transition.
One area where NIPR data has limitations is entity licensing. While entity license data is available through the NAIC's SBS system, NIPR's primary focus has historically been individual producers. Diligence teams should supplement NIPR and PDB searches with direct DOI record requests for entity license status, particularly in states that are less fully integrated with the NIPR infrastructure.
Transaction structure is the single most important variable in determining the scope of the licensing transition required. The difference between a stock sale and an asset sale produces categorically different regulatory obligations, and choosing a structure without fully understanding that difference can create closing risk, post-close operating gaps, and regulatory exposure.
In a stock sale, the acquirer purchases the equity of the target entity. The legal entity itself does not change: it is the same corporation or LLC holding the same licenses on the day after closing as on the day before. The entity license does not transfer in the technical sense because it never left the entity. For most states, this means the entity license survives the stock acquisition without a new license application. Individual producer licenses are similarly unaffected at the state level, because they are held by individuals whose employment relationship, not their license, is what changes.
However, stock sale license survival is not unconditional. Most states require disclosure of a change-of-control or change-of-ownership to the DOI within a defined period, typically ranging from 30 to 90 days post-close. Some states require this notification before close. A subset of states require the filing of an amended license application or a new controlling-person disclosure as a condition of continued license validity. Failure to comply with notification obligations, even where the license technically survives, can result in the DOI treating the license as void or placing it in a suspended status. Counsel must map notification requirements in every state in the target's footprint before closing.
In an asset sale, the acquirer purchases specified assets of the target, not its equity. Licenses are not assets in the traditional sense; they are regulatory permissions held by the licensee and not transferable to a third party by assignment. When an agency's assets are sold, the entity license remains with the selling entity, which may be wound down or repurposed. The acquiring entity must apply for its own entity licenses in each state where it intends to operate. Individual producers moving to the acquiring entity must obtain licenses in the acquiring entity if they are changing their licensed affiliation.
For agencies with books of business spanning many states, an asset acquisition can require a coordinated campaign of 30 or more simultaneous license applications. The time required to obtain approvals across all critical states, including states that do not participate in reciprocity or that have longer review timelines, must be built into the closing schedule. Acquirers who underestimate this lead time can find themselves owning customer relationships they are not yet licensed to service.
License Transition Counsel
Stock or asset, national or regional, producer licensing transitions require a sequenced plan built before LOI. We analyze your target's license inventory and build the critical-path timeline.
A carrier appointment is the mechanism by which an insurance carrier authorizes a specific licensed producer, whether individual or entity, to represent the carrier and transact its products. Appointments are distinct from licenses. A license is a regulatory credential issued by the state. An appointment is a contractual and regulatory designation made by the carrier and filed with the state DOI. Both must be in place for a producer to lawfully place business with a given carrier.
State DOIs maintain appointment records, and in most states carriers are required to file appointment and termination notices electronically, typically through NIPR. The state's record of an appointment is separate from the private producer agreement between the carrier and the agency, but both must align. An agency that holds an active appointment filing with the DOI but whose underlying producer agreement has been terminated operates in a gray area that could expose it to regulatory and civil liability.
Appointments have no fixed duration in most states. They remain in effect until terminated by the carrier or the producer. Annual renewal fees are required in some states; others do not require periodic renewal. The carrier can terminate an appointment at will in most jurisdictions, subject to any notice requirements in the producer agreement. This means that the ongoing commercial relationship with the carrier, governed by the producer agreement, is what practically maintains the appointment. If the commercial relationship ends, the appointment ends.
The most critical question in M&A due diligence is whether appointments are transferable. The answer is no. Appointments are not property of the agency in a legal sense. They are permissions granted by the carrier to a specific licensee. When an asset sale occurs, the selling agency's appointments cannot be transferred to the acquiring entity. The acquiring entity must obtain new appointments from each carrier. Even in a stock sale where the entity continues, carriers have contractual rights to terminate appointments upon change-of-control, meaning that appointment survival in a stock sale depends on the carrier exercising forbearance rather than on any automatic legal protection.
This reality creates one of the most significant commercial risks in insurance agency acquisitions. An acquirer that has not secured carrier appointment commitments before close could find itself holding an agency whose revenue depends on carrier relationships that the carriers are entitled to terminate. Appointment continuity should be addressed directly in carrier conversations during diligence, and key appointment commitments should be reflected in closing conditions or transition agreements where possible.
Producer agreement provisions governing change-of-control are among the most consequential contractual terms in an insurance agency acquisition. These provisions determine whether a carrier has the right to terminate the appointment when the agency changes ownership, and the conditions under which that right arises. Diligence review of every carrier agreement is not optional; it is a prerequisite to assessing the transaction's true risk profile.
Change-of-control clauses in producer agreements take several forms. The most straightforward are automatic termination clauses, which provide that the appointment terminates immediately and automatically upon a transfer of a controlling interest in the agency without the carrier's prior written consent. These clauses give the carrier maximum protection and the agency minimum flexibility. An automatic termination clause means that closing the transaction without carrier consent effectively ends the appointment on the closing date.
More common in practice are notice-and-consent clauses, which require the agency to notify the carrier of a pending change-of-control and give the carrier a defined period to evaluate whether to consent, re-negotiate terms, or elect termination. These clauses preserve carrier leverage while giving the agency an opportunity to seek approval. The notice period can range from 30 days to as much as six months in agreements with major carriers. Missing the notice deadline or closing without providing notice can trigger breach remedies and appointment termination.
A separate category involves assignment restrictions. Producer agreements commonly include provisions prohibiting assignment of the agreement to a third party without consent. In an asset sale, where the acquiring entity may seek to step into the target's producer agreements by operation of an assignment provision in the purchase agreement, these clauses create direct contractual obstacles. Carriers that are not parties to the purchase agreement are not bound by its terms, and an attempted assignment without carrier consent is typically void under the producer agreement.
Key-person provisions are another source of appointment termination risk. Agreements with major carriers sometimes designate named principals whose continued involvement is a condition of the appointment. If the named principal is exiting as part of the transaction, whether as seller, retiring founder, or departing key employee, the departure may independently trigger termination rights regardless of the ownership change. Counsel must identify all key-person designations in diligence and assess the impact of the contemplated management transition.
Diligence should produce a carrier-by-carrier matrix identifying: the revenue attributable to each carrier's book, the change-of-control and assignment provisions in each agreement, the notice obligations and timelines, and the carrier's likely posture toward the transaction. This matrix drives the pre-close carrier engagement strategy.
State DOI change-of-control notification requirements apply independently of carrier appointment obligations. Even where a stock acquisition does not technically require a new license application, states have enacted separate statutory and regulatory obligations requiring disclosure of ownership changes to the DOI. These obligations are a distinct compliance track from carrier relationship management, and failing to meet them is a standalone regulatory violation.
The specifics of DOI notification requirements vary substantially by state. Key variables include: the triggering threshold (some states trigger at 10 or 25 percent ownership change; others use 50 percent), the notification deadline (measured from closing, from signing, or from first knowledge of the transaction), the form and substance of the required filing, and whether the notification requires affirmative DOI acknowledgment or is purely informational. States that have adopted the PLMA in close conformity with the NAIC model tend to have similar frameworks, but state-specific variations are common enough that each state must be individually reviewed.
Some states go beyond notification and require prior approval of a controlling interest change in an insurance agency. These states are less common for agency-level transactions (as opposed to insurance company acquisitions, which are governed by holding company acts and require prior DOI approval in virtually every state), but they exist. Failing to identify a prior-approval state early in the transaction can result in closing a transaction before the required approval is obtained, creating a retroactive licensing violation.
In asset acquisitions, DOI interaction is more extensive because the acquiring entity must apply for new entity licenses. The new entity application typically requires disclosure of controlling persons, officers, directors, and key principals of the acquiring entity. This is a form of background screening by the DOI, and the completeness and accuracy of those disclosures is critical. Misstatements or omissions in license applications to state regulators carry serious consequences, including license denial, revocation, and potential criminal referral.
Practical management of multi-state DOI notification and application campaigns requires a structured tracking system. Counsel or a dedicated licensing consultant should maintain a state-by-state log tracking: notification deadline, filing submitted date, confirmation received, and any outstanding follow-up. Missing a state notification obligation in the post-close period because of disorganized tracking is an entirely preventable risk.
The Designated Responsible Licensed Producer is a regulatory position required by many states as a condition of entity licensing. The DRLP is an individual producer who holds an active individual license in the state, is designated on the entity license as the responsible party, and assumes personal accountability for the agency's compliance with insurance laws and regulations in that jurisdiction. The DRLP concept is embedded in the PLMA framework and adopted in some form by most states, though the terminology varies. Some states use the title "designated responsible producer," "qualifying officer," or "responsible licensed producer."
The practical significance of the DRLP in M&A is acute whenever the selling principals are departing. If the current DRLP is a founder, key principal, or employee who will not continue post-close, the agency faces a DRLP vacancy that must be resolved on or before the date the incumbent departs. States that require an active DRLP designation as a condition of maintaining the entity license will treat a vacancy as a license defect. Some states allow a cure period of 30 to 90 days to designate a replacement; others treat the vacancy as an immediate event of non-compliance.
Identifying and qualifying a replacement DRLP requires: confirming that the proposed individual holds an active individual producer license in the applicable state, verifying that the individual's lines of authority are appropriate for the agency's business, and filing the substitution with the DOI in the required format. In states where the DRLP must be designated through a formal amendment to the entity license, the filing must be completed before the incumbent's departure, not after.
In multi-state agencies, the DRLP designation exists separately in each state. A single individual may serve as DRLP in multiple states if they hold individual licenses in each, or different individuals may be designated by state. The transaction team must map the DRLP status in every state in the agency's footprint, identify which DRLPs are departing, confirm that replacements are qualified and licensed, and execute the substitution filings on a state-by-state basis timed to the transition.
Beyond the regulatory DRLP requirement, acquirers should assess the target's broader compliance officer function. Agencies with professional compliance programs have designated individuals responsible for license renewals, continuing education tracking, appointment maintenance, and DOI correspondence. If that function is embedded in a departing employee, the acquirer must either retain that person through a transition period or stand up a replacement function before close. Operating an agency without functional compliance oversight in the post-close period creates regulatory exposure that compounds over time.
Carrier Appointment Strategy
We review every producer agreement, map change-of-control termination rights, and structure the carrier engagement strategy before you sign. Submit transaction details to start the analysis.
Surplus lines authority is a distinct regulatory credential from a standard insurance producer license. A surplus lines broker license authorizes the holder to place coverage with non-admitted carriers, meaning insurers not licensed in the state but authorized to write surplus lines business there. The surplus lines market serves risks that admitted carriers will not write at standard terms, covering specialty, excess, and hard-to-place risks. For agencies with significant E&S books, surplus lines licensing is operationally critical and must be separately analyzed in M&A diligence.
In most states, a producer must first hold a standard producer license and then separately apply for, and qualify for, a surplus lines broker license. The surplus lines license has its own application, examination (in some states), and continuing education requirements. It is not a line of authority added to an existing license; it is a separate credential. Accordingly, an agency that holds surplus lines authority in a state holds two overlapping but legally distinct credentials in that state: the entity or individual producer license and the surplus lines broker license.
In a stock acquisition, both credentials generally continue in the surviving entity, subject to change-of-control notification requirements applicable to each. In an asset acquisition, both must be separately re-applied for by the acquiring entity. The timeline for obtaining surplus lines broker credentials may differ from the standard producer license timeline, and in states where surplus lines broker applicants must demonstrate financial responsibility through a bond or other mechanism, there may be additional lead time for those requirements.
Non-admitted carriers present a further layer of complexity in M&A. Non-admitted carriers are not subject to state rate and form regulation and are not covered by state guaranty funds. Producing business with non-admitted carriers requires strict compliance with surplus lines filing and tax obligations. In the acquisition of an agency with an E&S book, the acquirer must assess: whether non-admitted carriers that the agency currently uses are authorized to write surplus lines in the relevant states; whether the agency has been complying with surplus lines filing obligations, including affidavits and state-specific filings; and whether the diligence-identified non-admitted carrier relationships are transferable or require renegotiation.
Acquirers entering a new state's surplus lines market through acquisition should also confirm that the non-admitted carriers being acquired have current and valid surplus lines authorization in each state where placements are being made. Authorization can lapse or be withdrawn, and placements with an unauthorized non-admitted carrier are unlawful regardless of whether the placing broker holds a valid surplus lines license.
Agencies with national or regional footprints require licensing across many states, and managing that portfolio in an M&A context requires understanding three distinct regulatory mechanisms: reciprocity, countersignature requirements, and nonresident licensing. These mechanisms interact to determine how quickly and efficiently a multi-state licensing campaign can be executed in either a stock or an asset acquisition.
Reciprocity is the cornerstone of multi-state licensing efficiency. Under reciprocal licensing arrangements, a nonresident producer who holds an active license in their home state can obtain a nonresident license in a reciprocal state without taking the reciprocal state's examination, provided the reciprocal state's licensing requirements are substantially equivalent. Most states participate in reciprocity with most other states, but the reciprocity map is not universal. Certain state pairs do not have reciprocal arrangements, and some states impose additional requirements on nonresident applicants regardless of home-state licensing.
Nonresident license applications can generally be submitted through NIPR for states that have integrated their licensing systems with NIPR's gateway. Reciprocal states typically process these applications within two to four weeks if submitted with complete and accurate supporting information. Non-reciprocal states require applicants to demonstrate compliance with that state's individual requirements, which may include state-specific examination, background investigation, or both.
Countersignature requirements are a diminishing but not entirely eliminated category. Some states historically required that policies covering risks in the state be countersigned by a licensed resident producer of that state, even if the producing agent was a nonresident. Most states have eliminated countersignature requirements over the past decade, but a small number retain them in some form. For agencies operating in states with residual countersignature obligations, the M&A transition must account for identifying and maintaining qualified resident producers who can fulfill the countersignature function post-close.
In an asset acquisition requiring a full multi-state licensing build-out for the acquiring entity, the sequencing of applications matters. The home state resident license, which must be obtained first, establishes the basis for nonresident applications in reciprocal states. The home state application should be submitted as early in the transaction timeline as possible. Once the home state license issues, the nonresident campaign across reciprocal states can be launched in parallel, dramatically compressing the overall timeline compared to sequential state-by-state filing.
States with longer review timelines or non-reciprocal requirements, frequently including Florida, California, New York, and a handful of others, should be identified early as critical-path items. Closing timelines in multi-state asset acquisitions may need to be extended, or interim arrangements may be needed for states where licensing is not yet complete at the originally contemplated close date.
State insurance licensing regimes impose fitness standards on producers, and those standards apply not only to the licensed entity or individual at the time of initial licensing but also to the controlling persons of an entity seeking a license or disclosing a change-of-control. In an M&A context, this means that the fitness and background of the acquiring principals, officers, directors, and any individual designated as DRLP in the acquiring entity are subject to state DOI scrutiny as part of the licensing or change-of-control disclosure process.
The most significant fitness standard in insurance agency M&A involves felony criminal history. Section 1033 of title 18 of the United States Code prohibits any person convicted of a felony involving dishonesty or breach of trust from willfully engaging in the business of insurance affecting interstate commerce, or from willfully permitting such a person to engage in that business, without written consent from the applicable state insurance regulatory authority. The prohibition applies regardless of when the conviction occurred and regardless of whether the conviction was in a state or federal court.
A 1033 waiver is the written consent issued by the state insurance regulatory authority that allows an otherwise disqualified individual to participate in the business of insurance. Waivers are state-specific, discretionary, and not guaranteed. Each state that the individual intends to participate in must separately grant the waiver. The application process typically requires submission of detailed background information, documentation of the conviction, evidence of rehabilitation, and an explanation of the individual's proposed role in the insurance business. Review periods vary by state and can extend from several weeks to several months.
Beyond 1033, state fitness standards commonly include: license revocations or suspensions in any state, material misrepresentations on prior license applications, regulatory sanctions or consent orders, civil judgments involving dishonesty or fraud, and outstanding tax liens of material size. These factors can result in license application denial or heightened scrutiny and conditioning of approval.
In diligence, acquirers should run comprehensive background checks on all individuals who will serve as controlling persons, officers, directors, or DRLPs of the acquiring entity or the surviving entity in a stock acquisition where new ownership is being disclosed. The background check scope should match the regulatory disclosure scope. Where an individual presents a potential fitness concern, the analysis of whether a 1033 waiver is available and how long it will take must be integrated into the deal timeline and risk assessment before the transaction proceeds.
Sellers also bear disclosure obligations in this area. A seller who is aware of a principal's disqualifying conviction and fails to disclose it during diligence, or who structures a transaction to obscure the involvement of a disqualified person, creates serious legal exposure for both parties. Sellers and their counsel should proactively surface fitness issues early so that the parties can assess remediation options together rather than discovering the issue after signing.
The technical licensing and appointment requirements of an insurance agency acquisition only create real risk when they are addressed on the wrong timeline. The most common failure mode in insurance agency M&A is not a failure to understand what needs to happen, but a failure to start the licensing process early enough to have the required credentials in place by closing. Proper sequencing is a project management discipline as much as a legal one.
The sequencing challenge differs between stock and asset acquisitions. In a stock acquisition, the primary pre-close tasks are: completing the license inventory and confirming license status in all states, reviewing carrier producer agreements for change-of-control provisions and initiating carrier notification or consent processes, identifying any state DOI prior-approval requirements, and confirming DRLP continuity. These tasks can generally be accomplished within a typical 60-to-90-day signing-to-close period if started promptly after LOI execution.
In an asset acquisition, the timeline is more demanding. The home state license application for the acquiring entity, if not already licensed, must be submitted as soon as the acquiring entity is formed and its principals are identified. The home state application cannot wait for signing; in many transactions it should be filed in parallel with or shortly after the LOI. Once the home state license issues, typically four to eight weeks after filing, the nonresident campaign across reciprocal states can begin. Non-reciprocal states and states with longer review timelines must be filed in parallel with the home state if the closing timeline is tight.
Surplus lines applications, DRLP substitution filings, and 1033 waiver applications each have their own timelines that must be mapped against the master closing schedule. Critical-path analysis should identify the single longest-lead-time regulatory process and set the minimum closing date based on that constraint. Attempting to close before all required licenses are in place creates a gap period during which the acquirer cannot lawfully transact business in the unlicensed states.
Carrier appointment re-filing, while not a pre-close regulatory requirement in most cases, must also be planned pre-close. In an asset acquisition, the acquirer should have appointment applications prepared and ready to submit to each carrier immediately after close, because appointments in the new entity name are required before the entity can bind business with those carriers. Some carriers process appointment applications quickly; others take several weeks. Mapping the appointment re-filing timeline ensures that producers moving to the new entity are not operating in an appointment gap that creates unlicensed activity exposure.
The sequencing plan should be a living document maintained by counsel and updated as regulatory confirmations come in. It should be tied to the closing conditions checklist, with clear go/no-go gates for licensing milestones. A well-sequenced licensing transition is one of the most concrete ways legal counsel adds value in insurance agency M&A, because it is the difference between a clean close and a close that creates immediate regulatory and operational exposure.
In a stock sale, the legal entity holding the license does not change. The corporate shell continues to exist, and the entity license generally survives without requiring a new application. However, the acquiring party must review the license terms, state DOI rules, and any change-of-control provisions that could trigger a notification or approval requirement. Some states require affirmative disclosure of the ownership change to the DOI, and failure to notify within prescribed deadlines can place the license in jeopardy. Legal counsel should confirm survival treatment on a state-by-state basis before close.
A license is issued by the state DOI and authorizes a producer (individual or entity) to transact insurance in that state. An appointment is a contractual and regulatory designation by which a specific carrier authorizes that licensed producer to represent and sell its products. Licenses are held by the producer; appointments are granted by carriers and must be separately maintained. In an M&A transaction, a license may survive or be transferred, but appointments are carrier-controlled and almost always require affirmative re-appointment by each carrier following a change-of-control event. Both must be analyzed independently.
Processing timelines vary significantly by state. Resident license applications in the home state may process in days if submitted through NIPR. Nonresident applications in reciprocal states often process within two to four weeks. States that require more thorough background review, fingerprinting, or that have manual review processes can take four to eight weeks or longer. In asset acquisitions where the acquirer must obtain fresh licenses, the aggregate time across a multi-state book can run two to four months when sequenced efficiently. Counsel should map the critical-path states early in diligence and build transition timelines accordingly.
The Designated Responsible Licensed Producer is the individual named on a business entity license who is accountable for the agency's compliance with insurance laws. Many states require every licensed entity to designate a DRLP. If the DRLP departs due to the M&A transaction, resigns, or loses their individual license, the entity's license may be suspended or revoked in some states unless a replacement is designated within a prescribed cure period. In transactions where key principals are exiting, the acquirer must identify a qualified replacement DRLP in each state, obtain any required individual licensing for that person, and file the substitution before the incumbent's departure.
Most state DOIs do not have a prior-approval regime for insurance agency M&A transactions the way that insurance company acquisitions do. However, many states require notification of a change-of-control within a defined period, and some require that the acquirer file updated ownership information or complete a new entity licensing application. A small number of states have heightened scrutiny for controlling-interest changes. The obligation is generally notification rather than prior approval, but the distinction matters: failure to notify on time can result in license suspension even when approval is not required. Each state must be checked individually.
Producer appointment agreements commonly contain change-of-control provisions that automatically terminate the appointment upon a transfer of controlling interest in the agency. Some contracts define control as acquisition of more than 50 percent of equity; others use a lower threshold or define it by reference to board composition or management authority. Additional triggers include assignment-without-consent clauses, loss of key-person provisions tied to named principals, and material change-of-business clauses. Even where there is no automatic termination, many carrier agreements give the carrier a discretionary termination right upon change-of-control. Each carrier agreement must be reviewed individually in diligence.
Surplus lines broker licenses are separate regulatory credentials from standard producer licenses and are issued to individuals or entities authorized to place coverage with non-admitted carriers. They carry their own application, examination, and continuing education requirements and are not automatically included in or attached to a standard producer license. In an M&A transaction, surplus lines licenses must be tracked separately in diligence. Asset acquisitions require fresh surplus lines broker applications. Stock acquisitions require verification that the entity's surplus lines license does not contain change-of-control restrictions. If the agency's book relies heavily on E&S placements, the acquirer must confirm continuity of surplus lines authority before close.
Section 1033 of the federal criminal code prohibits individuals convicted of certain felonies involving dishonesty or breach of trust from participating in the business of insurance without prior written consent from the applicable state insurance regulator. A 1033 waiver is that consent. In M&A diligence, acquirers must run criminal background checks on all prospective controlling principals, officers, and DRLP candidates. If any individual has a disqualifying conviction, a 1033 waiver application must be submitted and approved by each state DOI where the individual will participate in the business before close. Waivers are discretionary, state-specific, and can take weeks to months. Failure to obtain a required waiver exposes the agency and the individual to criminal liability.
Tell us about your deal. We review every submission and respond within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790